A5032379353- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- Glioma Diagnosis and Treatment
- Breast Cancer Treatment Studies
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Radiopharmaceutical Chemistry and Applications
- Chronic Lymphocytic Leukemia Research
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Fibroblast Growth Factor Research
- Chromatin Remodeling and Cancer
- Sarcoma Diagnosis and Treatment
- Cancer-related Molecular Pathways
- Click Chemistry and Applications
- PARP inhibition in cancer therapy
- Radiomics and Machine Learning in Medical Imaging
- Estrogen and related hormone effects
- Synthesis and biological activity
- Breast Lesions and Carcinomas
- Meningioma and schwannoma management
- Bone health and treatments
- Medical Imaging Techniques and Applications
Institut Català d'Oncologia
2016-2025
Institut d'Investigació Biomédica de Bellvitge
2016-2025
Hospital Universitario Virgen de la Arrixaca
2025
GEICAM – Spanish Breast Cancer Group
2011-2024
Bellvitge University Hospital
2015-2024
Instituto de Oncología de Rosario
2024
Duran i Reynals Hospital
2011-2023
Centro Hospitalar de Lisboa Central
2022
Universitat de Barcelona
2019-2021
Hospital Prof. Dr. Fernando Fonseca
2021
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
Data suggest that the adjuvant use of bisphosphonates reduces rates recurrence and death in patients with early-stage breast cancer. We conducted a study to determine whether treatment zoledronic acid, addition standard therapy, would improve disease outcomes such patients.In this open-label phase 3 study, we randomly assigned 3360 receive systemic therapy either or without acid. The acid was administered every 4 weeks for 6 doses then months complete 5 years treatment. primary end point...
The recurrence score based on the 21-gene breast-cancer assay has been clinically useful in predicting a chemotherapy benefit hormone-receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, axillary lymph-node-negative breast cancer. In women with positive lymph-node disease, role of respect to adjuvant is unclear.In prospective trial, we randomly assigned HER2-negative cancer, one three lymph nodes, and 25 or lower (scores range from 0 100, higher scores indicating...
Pre-clinical studies have demonstrated synergistic anti-tumour effects of chemotherapy (CT) and zoledronic acid (ZOL). Within the AZURE trial, designed to determine whether addition ZOL neoadjuvant therapy improves disease outcomes, a subgroup received CT. We report retrospective evaluation comparing pathological response in primary tumour between treatment groups. In total, 205 patients CT±ZOL (CT+ZOL, n=102; CT, n=103). The end point was pathologically assessed residual invasive size...
We conducted a multicenter, 2-stage, open-label, phase II trial to assess the efficacy and safety of dacomitinib in adult patients with recurrent glioblastoma (GB) epidermal growth factor receptor gene (EGFR) amplification or without variant III (EGFRvIII) deletion.Patients first recurrence were enrolled 2 cohorts. Cohort A included EGFR EGFRvIII mutation. B Dacomitinib was administered (45 mg/day) until disease progression/unacceptable adverse events (AEs). Primary endpoint progression-free...
Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has not been compared with that chemotherapy in a phase III trial.PEARL multicentre, randomised study which patients aromatase inhibitor (AI)-resistant MBC were included two consecutive cohorts. In cohort 1, 1 : to palbociclib exemestane or capecitabine. On discovering new evidence about...
Adjuvant bisphosphonates improve disease outcomes in postmenopausal early breast cancer (EBC) but the long-term effects are poorly described. The AZURE trial (ISRCTN79831382) was designed to determine whether adjuvant zoledronic acid (ZOL) improves EBC. Previous analyses showed no effect on overall identified benefits women. Here we present risks and of ZOL with 10-years follow-up.3360 patients stage II/III were included an academic, international, phase III, randomized, open label trial....
Abstract Background Standard treatment for glioblastoma is radiation with concomitant and adjuvant temozolomide 6 cycles, although the optimal number of cycles has long been a subject debate. We performed phase II randomized trial investigating whether extending more than improved outcome. Methods Glioblastoma patients treated at 20 Spanish hospitals who had not progressed after were centrally to stop (control arm) or continue (experimental up total 12 same doses they receiving in cycle 6....
The cyclin-dependent kinase 4 and 6 inhibitor palbociclib in combination with letrozole has become a standard first-line treatment for patients endocrine-sensitive, hormone receptor-positive, ERBB2-negative advanced breast cancer. Meanwhile, the antiestrogen fulvestrant was shown to be superior anastrozole absence of inhibition this patient population.To assess whether is when combined scenario.In international, randomized, open-label, phase 2 clinical study conducted from July 30, 2015,...
FGFR genomic alterations (amplification, mutations, and/or fusions) occur in ∼8% of gliomas, particularly FGFR1 and FGFR3. We conducted a multicenter open-label, single-arm, phase II study selective FGFR1-3 inhibitor, infigratinib (BGJ398), patients with FGFR-altered recurrent gliomas.Adults recurrent/progressive gliomas harboring received oral 125 mg on days 1 to 21 28-day cycles. The primary endpoint was investigator-assessed 6-month progression-free survival (PFS) rate by Response...
Abstract Purpose: In hormone receptor–positive (HR+)/HER2− metastatic breast cancer (MBC), it is imperative to identify patients who respond poorly cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) and discover therapeutic targets reverse this resistance. Non-luminal subtype high levels of CCNE1 are candidate biomarkers in setting, but further validation needed. Experimental Design: We performed mRNA gene expression profiling correlation with progression-free survival (PFS) on 455 tumor...
We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea patients with recurrent glioblastoma (GBM) who were either on or not enzyme-inducing anti-epileptic drugs (EIAEDs). A total 231 GBM at first recurrence from 21 institutions 10 countries enrolled. All received 500 mg twice a day. Imatinib was administered 600 per day for EIAEDs and if EIAEDs. The primary end point radiographic response rate secondary points safety, progression-free survival 6 months (PFS-6), overall...
To assess management patterns and outcome in patients with glioblastoma multiforme (GBM) treated during 2008–2010 Spain. Retrospective analysis of clinical, therapeutic, survival data collected through filled questionnaires from histologically confirmed GBM diagnosed 19 Spanish hospitals. We identified 834 (23% aged >70 years). Surgical resection was achieved 66% patients, although the extent surgery by postoperative MRI only 41%. There were major complications 14% age independent predictor...
Glioblastoma (GBM) or grade IV glioma is the most common primary brain tumor in adults. Standard treatment median overall survival (OS) only 14-15 months and less than 10% of patients will survive 5 years after diagnosis. There no standard recurrent GBM OS ranges from 3 to 9 months. 1 vascularized human tumors cells produce vascular endothelial growth factor (VEGF). Bevacizumab, a humanized monoclonal antibody against VEGF, has demonstrated activity vitro phase II trials relapse, as well III...
Glioblastoma (GB) is the most common brain malignancy and accounts for over 50% of all high-grade gliomas. Radiotherapy (RT) with concomitant adjuvant temozolomide (TMZ) chemotherapy current standard care patients newly diagnosed GB up to age 70. Recently, a new has been adopted elderly (≥ 65 years) based on short course RT TMZ. Several clinically relevant molecular markers that assist in diagnosis prognosis have recently identified. The treatment recurrent not well defined, decision-making...
Abstract Background: The Phase 2 PARSIFAL study assessed whether fulvestrant (FUL) or letrozole (LET) was the optimal endocrine partner for cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) palbociclib (PAL) in patients (pts) with untreated, endocrine-sensitive, hormone receptor-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) first-line setting. This trial failed to demonstrate an improvement progression-free survival (PFS) of PAL+FUL over PAL+LET (Llombart-Cussac et al. Jama...
To compare different methods in order to assess adherence and persistence with oral endocrine therapy women diagnosed breast cancer (BC) Catalonia. This study covered all newly stage I, II or IIIa BC positive hormone receptors at six hospitals Catalonia (Spain) 2004. Adherence was assessed on the basis of physician report patient self-report using a telephone questionnaire. Persistence measured by refill prescriptions. We used Kappa index measures logistic regression evaluate...
We assessed the efficacy and safety of bevacizumab (BEV) through multiple lines in patients with recurrent glioblastoma who had progressed after first-line treatment radiotherapy, temozolomide, BEV. TAMIGA (NCT01860638) was a phase II, randomized, double-blind, placebo-controlled, multicenter trial adult glioblastoma. Following surgery, newly diagnosed received consisting radiotherapy plus temozolomide BEV, followed by six cycles then BEV monotherapy until disease progression (PD1)....